Review: Precision Medicine for Multiple Sclerosis

Key decision points in multiple sclerosis (MS) management would benefit from precision medicine—using information about an individual’s genomics, environment, and lifestyle, not just their signs and symptoms—to subtype their disease and make personalized decisions about their treatment.

Read More...

New Tool Allows Early Prediction of Disease Course in Multiple Sclerosis

Rendering of orange microglia cells damaging the myelin sheath of neuron axons

Using machine learning, researchers in the Brigham Multiple Sclerosis Center and colleagues have developed a tool for predicting what the outcome of patients with recently diagnosed MS will be in 10 years.

Read More...

Novel Therapeutic Target Identified for Multiple Sclerosis

Blue 3D rendering of microRNA strands

Researchers at the Ann Romney Center for Neurologic Diseases at the Brigham, and colleagues have affirmed miR-92a as a powerful, clinically relevant target in multiple sclerosis and give preliminary information about the effects of inhibiting miR-92a in central nervous system autoimmune disease.

Read More...

Study: Multiple Sclerosis Drug Shows Positive Results for Pediatric Patients

Tanuja Chitnis
Tanuja Chitnis

A first-of-its-kind clinical trial at Brigham and Women’s Hospital (BWH) has shown that administering an oral multiple sclerosis (MS) drug to patients younger than 18 years of age is safe and 82 percent more effective than an injectable treatment that is the current standard of care. Read More

Multiomics Approach Implicates Tissue Extracellular Vesicles in Atherosclerosis and Calcific Aortic Valve Stenosis

Using a novel method, Brigham and Women’s Hospital researchers completed the first comparative proteomics study of pathogenesis in calcified carotid arteries and aortic valves (AVs), identifying unique drivers of atherosclerosis versus AV stenosis and implicating extracellular vesicles in both diseases.

Read More...

Serum-based Assay Validated for Care of Patients With MS

Researchers at Brigham and Women’s Hospital developed the Multiple Sclerosis Disease Activity (MSDA) Test, a multiprotein, serum-based biomarker assay for MS diagnosis, and have reported clinical validation of the assay.

Read More...

Blood Tests May Identify Which Patients With Stable MS Can Discontinue Treatment

close up picture of dripping liquid from pipette into test tube

Serum biomarkers are becoming increasingly investigated for risk profiling in MS. Researchers at Brigham and Women’s Hospital have found that changes in two of them after treatment is stopped can signal impending disease activity.

Read More...

Nasal Monoclonal Antibody Suppresses Inflammatory Response in COVID-19

In a new study, a Brigham team determined how nasal foralumab modulates inflammation and describes a potential novel avenue for treating not just COVID-19 but also autoimmune diseases.

Read More...

Review: Myelin Oligodendrocyte Glycoprotein Antibody Disease

Various demyelinating diseases, including optic neuritis, transverse myelitis, acute disseminated encephalomyelitis (ADEM), and cerebral cortical encephalitis, are now recognized as a spectrum of diseases associated with high titers of autoantibodies that target myelin oligodendrocyte glycoprotein (MOG).

Read More...

Economic Burden of Neuromyelitis Optica Spectrum Disorders Quantified From Patient Point of View

Brigham and Women’s Hospital researchers recently conducted the first study of patient-reported data on the economic burden of neuromyelitis optica spectrum disorders (NMOSD). Specifically, they characterized the direct and indirect costs of relapse events (ED visits and hospitalizations).

Read More...